vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4223 163521-12-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vilazodone
  • viibryd
  • vilazodone hydrochloride
  • vilazodone HCl
A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.
  • Molecular weight: 441.54
  • Formula: C26H27N5O2
  • CLOGP: 4.33
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 102.29
  • ALOGS: -3.56
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.76 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15.66 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2011 FDA FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 243.18 20.93 117 5103 55268 50544636
Abnormal dreams 136.69 20.93 47 5173 9330 50590574
Hallucination 122.63 20.93 70 5150 46587 50553317
Persistent genital arousal disorder 99.78 20.93 18 5202 234 50599670
Serotonin syndrome 89.80 20.93 46 5174 24667 50575237
Sleep paralysis 74.88 20.93 16 5204 516 50599388
Nightmare 73.48 20.93 35 5185 16051 50583853
Agitation 72.73 20.93 53 5167 53331 50546573
Anxiety 72.08 20.93 90 5130 177516 50422388
Paraesthesia 70.94 20.93 74 5146 120169 50479735
Mania 59.97 20.93 27 5193 10889 50589015
Insomnia 57.57 20.93 80 5140 174785 50425119
Suicide attempt 46.03 20.93 40 5180 51692 50548212
Anger 43.78 20.93 22 5198 11311 50588593
Completed suicide 42.85 20.93 60 5160 131829 50468075
Feeling abnormal 42.13 20.93 58 5162 125434 50474470
Crying 41.51 20.93 26 5194 20390 50579514
Seizure 40.35 20.93 55 5165 117819 50482085
Dizziness 40.10 20.93 101 5119 346268 50253636
Tremor 39.91 20.93 54 5166 114849 50485055
Depression 32.69 20.93 60 5160 165363 50434541
Muscle twitching 32.24 20.93 20 5200 15411 50584493
Sleep terror 29.48 20.93 8 5212 715 50599189
Irritability 29.43 20.93 24 5196 28402 50571502
Panic attack 28.13 20.93 20 5200 19322 50580582
Withdrawal syndrome 27.47 20.93 19 5201 17571 50582333
Diarrhoea 24.94 20.93 123 5097 588353 50011551
Nausea 24.83 20.93 140 5080 705258 49894646
Hypnagogic hallucination 24.47 20.93 5 5215 129 50599775
Tardive dyskinesia 22.02 20.93 12 5208 7267 50592637
Electric shock sensation 21.47 20.93 5 5215 240 50599664

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serotonin syndrome 143.93 32.05 50 1758 17462 29555257
Suicidal ideation 143.57 32.05 60 1748 34656 29538063
Completed suicide 91.97 32.05 61 1747 90185 29482534
Mania 53.26 32.05 20 1788 8643 29564076
Sexual dysfunction 49.18 32.05 17 1791 5797 29566922
Anxiety 39.01 32.05 36 1772 85329 29487390
Overdose 37.12 32.05 34 1774 79785 29492934

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 206.78 22.67 101 4834 66441 64427356
Serotonin syndrome 141.30 22.67 66 4869 39216 64454581
Completed suicide 106.77 22.67 107 4828 224307 64269490
Persistent genital arousal disorder 98.82 22.67 17 4918 228 64493569
Abnormal dreams 83.55 22.67 31 4904 10325 64483472
Anxiety 75.62 22.67 85 4850 202564 64291233
Hallucination 67.72 22.67 51 4884 72737 64421060
Mania 60.46 22.67 28 4907 16258 64477539
Sleep paralysis 55.72 22.67 12 4923 546 64493251
Paraesthesia 54.55 22.67 59 4876 134463 64359334
Anger 52.08 22.67 25 4910 15716 64478081
Insomnia 51.10 22.67 69 4866 197767 64296030
Nightmare 50.86 22.67 27 4908 20966 64472831
Tremor 48.22 22.67 58 4877 148172 64345625
Crying 46.32 22.67 25 4910 20065 64473732
Agitation 39.78 22.67 41 4894 88326 64405471
Irritability 39.23 22.67 28 4907 36718 64457079
Intentional overdose 39.17 22.67 41 4894 89903 64403894
Suicide attempt 37.61 22.67 36 4899 70971 64422826
Off label use 35.13 22.67 117 4818 632689 63861108
Muscle twitching 33.92 22.67 20 4915 18978 64474819
Memory impairment 30.26 22.67 35 4900 85647 64408150
Feeling abnormal 29.11 22.67 43 4892 133559 64360238
Dizziness 24.19 22.67 80 4855 430083 64063714
Seizure 23.30 22.67 44 4891 166848 64326949

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX24 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D017367 Serotonin Uptake Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35941 serotonin agonists
CHEBI has role CHEBI:50949 SSRI

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Suicidal contraindication 267073005
Serotonin syndrome contraindication 371089000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.56 acidic
pKa2 13.13 acidic
pKa3 8.58 Basic
pKa4 1.41 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 7834020 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8193195 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8236804 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 7834020 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8193195 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8236804 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 7834020 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8193195 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL 8236804 June 5, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
20MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
40MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
10MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY
20MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY
40MG VIIBRYD ALLERGAN N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR IC50 9.30 IUPHAR CHEMBL
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 9.70 IUPHAR CHEMBL
D(3) dopamine receptor GPCR AGONIST IC50 7.15 IUPHAR
Histamine H1 receptor GPCR AGONIST IC50 6.50 IUPHAR
5-hydroxytryptamine receptor 4 GPCR AGONIST IC50 6.60 IUPHAR
Adrenergic receptor alpha-2 GPCR IC50 5.22 CHEMBL
D(2) dopamine receptor GPCR AGONIST IC50 6.18 IUPHAR
Adrenergic receptor alpha-1 GPCR IC50 5.70 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.41 CHEMBL
5-hydroxytryptamine receptor 1B GPCR IC50 5.30 CHEMBL
D(2) dopamine receptor GPCR IC50 6.18 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 9.52 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 9.30 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.82 CHEMBL
5-hydroxytryptamine receptor 7 GPCR IC50 5.52 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 5.70 CHEMBL
5-hydroxytryptamine receptor 4 GPCR IC50 6.60 CHEMBL
D(3) dopamine receptor GPCR IC50 7.15 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 5.40 CHEMBL
D(4) dopamine receptor GPCR IC50 5.47 CHEMBL
5-hydroxytryptamine receptor 6 GPCR IC50 5.52 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel IC50 5.37 CHEMBL

External reference:

IDSource
4030483 VUID
N0000182438 NUI
D09698 KEGG_DRUG
163521-08-2 SECONDARY_CAS_RN
4030483 VANDF
4030484 VANDF
C1530072 UMLSCUI
CHEBI:70707 CHEBI
YG7 PDB_CHEM_ID
CHEMBL439849 ChEMBL_ID
CHEMBL1615374 ChEMBL_ID
D000069503 MESH_DESCRIPTOR_UI
DB06684 DRUGBANK_ID
7427 IUPHAR_LIGAND_ID
7638 INN_ID
S239O2OOV3 UNII
6918314 PUBCHEM_CID
1086768 RXNORM
179494 MMSL
27744 MMSL
d07740 MMSL
013753 NDDF
013754 NDDF
702837008 SNOMEDCT_US
715638004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1110 TABLET 10 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1120 TABLET 20 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1140 TABLET 40 mg ORAL NDA 32 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2043 TABLET, FILM COATED 40 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2044 TABLET, FILM COATED 20 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2045 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-352 TABLET 10 mg ORAL ANDA 32 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-353 TABLET 20 mg ORAL ANDA 32 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-354 TABLET 40 mg ORAL ANDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4624 TABLET 40 mg ORAL NDA 29 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4627 TABLET 20 mg ORAL NDA 29 sections
vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 60505-4772 TABLET 10 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 60505-4773 TABLET 20 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 60505-4774 TABLET 40 mg ORAL NDA authorized generic 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-232 TABLET, FILM COATED 10 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-233 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 62332-234 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections